Geron (GERN) Shares Up 4.8%

Shares of Geron Co. (NASDAQ:GERN) shot up 4.8% on Monday . The company traded as high as $6.10 and last traded at $5.91. 16,680,543 shares traded hands during mid-day trading, an increase of 216% from the average session volume of 5,277,863 shares. The stock had previously closed at $5.64.

A number of research firms recently weighed in on GERN. Piper Jaffray restated a “buy” rating and issued a $7.00 price target on shares of Geron in a research note on Monday, March 19th. Stifel Nicolaus lifted their price target on Geron from $2.50 to $4.00 and gave the company a “hold” rating in a research note on Sunday, March 18th. BidaskClub upgraded Geron from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 17th. ValuEngine raised Geron from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. Finally, Zacks Investment Research cut Geron from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.50.

How to Become a New Pot Stock Millionaire

The firm has a market cap of $906.09, a price-to-earnings ratio of -32.83 and a beta of 2.77.

Geron (NASDAQ:GERN) last issued its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.41 million. Geron had a negative return on equity of 25.25% and a negative net margin of 2,621.22%. The business’s revenue for the quarter was up 103.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.05) earnings per share. equities analysts expect that Geron Co. will post 0.01 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of GERN. Parametric Portfolio Associates LLC raised its holdings in Geron by 59.4% during the second quarter. Parametric Portfolio Associates LLC now owns 47,976 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 17,877 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in Geron by 42.0% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 82,426 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 24,370 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Geron by 783.9% during the third quarter. Russell Investments Group Ltd. now owns 363,990 shares of the biopharmaceutical company’s stock worth $794,000 after purchasing an additional 322,810 shares during the last quarter. Creative Planning raised its holdings in Geron by 69.8% during the fourth quarter. Creative Planning now owns 308,523 shares of the biopharmaceutical company’s stock worth $555,000 after purchasing an additional 126,810 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new position in Geron during the fourth quarter worth $314,000. 36.89% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3302804/geron-gern-shares-up-4-8.html.

About Geron

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New England Nuclear  & The Competition Financial Comparison
New England Nuclear & The Competition Financial Comparison
Monarch Casino & Resort  & Its Competitors Head-To-Head Analysis
Monarch Casino & Resort & Its Competitors Head-To-Head Analysis
PayPal  Issues FY18 Earnings Guidance
PayPal Issues FY18 Earnings Guidance
McKesson  Releases FY19 Earnings Guidance
McKesson Releases FY19 Earnings Guidance
Save and Gain  Trading 5.4% Higher  This Week
Save and Gain Trading 5.4% Higher This Week
BritCoin  Reaches 1-Day Volume of $965.00
BritCoin Reaches 1-Day Volume of $965.00


© 2006-2018 Ticker Report. Google+.